Descartes-08 not checked
Cartesian Therapeutics · Decartes-08
FollowEvery change as it happens, and a Monday email
Trials
5 active
6 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA”In the company’s words, NCT04146051 on ClinicalTrials.gov
- Tested for
- Myasthaenia Gravis, Myasthenia Gravis, Generalized, Systemic Lupus Erythematosus (SLE), Antisynthetase Syndrome, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Main trialPhase 3
- “The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.”In the company’s words, NCT06799247 on ClinicalTrials.gov
- Other names
- Decartes-08 · CAR-T cells
Other drugs for Myasthaenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- TelitaciceptRemeGen · Phase 3
- Efgartigimodargenx · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- IptacopanNovartis · Phase 3
Coming up4
- 1 DecPhase 2 trial completes · ClinicalTrials.gov
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Dec 2026 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | |
| Phase 2Active, not recruiting | 5 Jan 2026 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | |
| Phase 2Active, not recruiting | 1 Dec 2026 | Descartes-08 for Patients With Systemic Lupus Erythematosus | |
| Phase 2Recruiting | Nov 2027 | Descartes-08 in Autoantibody Myositis | |
| Phase 1/2Recruiting | Dec 2027 | Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders | |
| Phase 1Terminated | 19 Apr 2021 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026